



FOR IMMEDIATE RELEASE

NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

**VENTRIPOINT DIAGNOSTICS' THIRD QUARTER PROGRESS
HAS MOVED UP COMMERCIAL LAUNCH DATE**

***Unaudited Financial Statements and Management Discussion and Analysis
Have Been Filed***

SEATTLE, December 8, 2008 – VentriPoint Diagnostics (TSX: VPT) today announced that it has filed its management discussion and analysis (“MD&A”), as well as its unaudited financial results for the three months ended September 30, 2008, with the Canadian Securities Administrators through the SEDAR filing system, viewable at www.sedar.com.

Development Highlights

In its MD&A, VentriPoint announced that among the Company’s highlights it completed both System and Alpha testing in October 2008 ahead of schedule. Additionally, Beta testing commenced on October 12, 2008, which comprised a limited release of the VentriPoint Diagnostic System (“VDS”) to users outside of the Company for testing before official release. As a result of early testing being completed ahead of schedule, the Company is on track to release its first commercial product in January 2009.

“The completion of System and Alpha testing, and deployments of Beta systems into potential customer sites are substantial milestones behind us, moving us closer to the first commercial offering of the VentriPoint Diagnostic System,” commented Joseph Ashley, CEO of VentriPoint Diagnostics. “These achievements further support the Company’s efforts to go to market nearly two months sooner than originally planned. We are confident that analyses of patient studies performed with the Beta testing will validate prior results, which show that the VDS creates accurate reconstructions and measurements of disease impacted hearts in a rapid, cost effective manner that is not currently available in the marketplace.”

Other recent milestones achieved include the successful implementation of technological advances that improve both the effectiveness and efficiency of study results; a limited private unveiling of a prototype VDS at a private off-site room during the American Heart Association’s Scientific Sessions meeting; and additional collaboration agreements with key congenital heart disease institutions.

Third Quarter Financial Highlights

In its unaudited financial results, VentriPoint reported a consolidated net loss of \$1,190,552 for the three months ended September 30, 2008, or \$0.03 per share, compared to a net loss of \$205,826, or \$0.01 per share, for the three months ended September 30, 2007. The increase in net loss is attributed to planned expenditures to accelerate the development of the VentriPoint Diagnostic System.

For the three months ended September 30, 2008, research and development expenses totaled \$773,500, compared to \$177,956 for the three months ended September 30, 2007. The largest research and development expense for the third quarter was payroll costs to build a high caliber R&D team.

VentriPoint reported a foreign exchange loss of \$120,125 resulting from the currency exchange rate used to translate Canadian monetary items into the US.

About VentriPoint Diagnostics Ltd.

VentriPoint creates diagnostic tools to monitor patients with heart disease – the number one cause of death in developed countries. By using images produced from existing medical imaging systems, the VentriPoint Diagnostic System generates critical heart measurements in a rapid and inexpensive manner not currently available. This breakthrough diagnostic tool is based upon technology received by VentriPoint through its exclusive technology license with the University of Washington. The VentriPoint Diagnostic System, together with its associated online service, is being developed for a variety of heart related disease states, including congenital heart disease.

For further information, please contact:

VentriPoint Diagnostics Ltd.

Edward Garth, Chief Financial Officer

Telephone: (206) 283-0221, ext. 402

Facsimile: (206) 283-2309

CHF Investor Relations

Christopher Haldane, Account Manager

Telephone: (416) 868-1079 ext.237

Facsimile: (416) 868-6198

To receive press release, please email chris@chfir.com and mention VentriPoint in the Subject line

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporations filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.